The decline of rate and mortality of acute myocardial infarction. Almost there, still a long way to go

In the last decades, reduction of both hospitalizations and mortality due to acute myocardial infarction (AMI) has been reported in many developed countries and attributed, at least in part, to risk modification at population level. Several other mechanisms, such as prompt and effective coronary revascularization, have also been shown to be instrumental in the improvement of patient prognosis. Indeed, a growing number of patients is now appropriately managed in the acute and post-acute phase of the index event. Evaluation of residual myocardial ischaemia as well as appropriate administration of drugs, including statins, beta-blockers, ACE inhibitors and dual antiplatelet therapy, represent the mainstream of therapeutical management for most of these patients. In this issue of the journal, Sulo et al. has updated information on trends of incident AMI in Norway according to data of the ‘Cardiovascular Disease in Norway 1994–2014’ project. They observed a yearly decline of AMI diagnoses by 2.6% and 2.8% in men and women, respectively, that contributed to the reduction of both AMI hospitalization and mortality. Declining rates were observed in all age groups. In 18% of men and 23.3% of women, the first AMI was fatal and in 20.1% of cases, the death occurred at home, work place, public places, nursing home or during transportation. As appropriately recognized by the authors, the observational design of the study prevents an appropriate evaluation of the factors responsible for the observed changes. It is likely that modifications in the levels of some risk factors, such as smoking or uncontrolled arterial hypertension, might have played a positive role. Whilst there might be regional differences and the data presented by Sulo et al. might not be entirely representative of other countries, similar trends can also be observed in other developed countries. Hence it is appropriate to ask whether the contemporary clinical care is on the right track and whether we should expect further reduction of mortality due to AMI in the forthcoming years. In our opinion, this is unlikely for several reasons. Despite organizational and medical management advances of the acute phase of AMI that contributed to a significant decline of in-hospital mortality, death rates before hospital admission and after hospital discharge have not decreased as we would have wished. As shown by Sulo et al., the mortality due to ventricular fibrillation that characterizes the early phase of acute coronary syndrome and prevents admission and proper treatment of patients remains high and is only partially affected by medical and healthcare organization strategies. Drugs such as beta-blockers, angiotensinconverting enzyme inhibitors and statins may show their preventive effects on the electrophysiological and haemodynamic changes associated with an acute coronary event only in patients in whom cardiac diagnosis has already been made. This leaves the so-called apparently healthy subjects particularly vulnerable. Present knowledge allows risk modifications in the general population to be proposed but they require interventions that are difficult to apply without a consistent support and funding from national healthcare systems. In this context, the 2016 European Guidelines on cardiovascular (CV) disease prevention in clinical practice recommended ‘systematic CV risk assessment in men >40 years of age and in women >50 years of age or post-menopausal with no known CV risk factors may